-
LOCALLY SOURCED
To find and license promising
development candidates from
domestic biotech/pharma
companies and universities -
REGIONALLY FINANCED
To establish sources of financing
from regional investment
communities -
GLOBALLY DEVELOPED
To develop assets up to human
PoC(Proof of Concept) globally
Pipeline
We have initially focused on small molecular entities (SME) for the treatment of inflammatory and fibrotic diseases and are gradually expanding our interests to the immuno-oncology field with advanced modalities.
News
Bridge Biotherapeutics Announces Data Presentation from First-in-Human Study of BBT-877 for Idiopathic Pulmonary Fibrosis
Postive Interim Results from Ongoing Phase 1 Trial Presented at ATS 2019 Bridge Biotherapeutics Inc., a clinical-stage biotech company developing novel therapeutics for areas with high unmet medical needs, announced that the company presented interim data from a Phase I clinical study on BBT-877, a drug candidate for treatment of idiopathic pulmonary fibrosis (IPF), at the American Thoracic S...
Read More-
LEARN MORE ABOUT US
-
CONTACT INFORMATION
HQ: Suite 903-2, Bldg B, Innovalley, 253 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13486 Republic of Korea
US Office: Bridge Biotherapeutics, Inc. in JLABS@TMC, 2450 Holcombe Blvd. Houston, TX 77021, USADirector, Jong-jin Lim (jong-jin.lim@bridgebiorx.com)
Manager, Joengbin Ahn (Joengbin.ahn@bridgebiorx.com)